Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 6/20 | 0.52 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.52 |
| ▸ | CCNA1 | P78396 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.36 |
| ▸ | WNT3A | P56704 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.35 |
| ▸ | CDK3 | Q00526 | 1/20 | 0.35 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5225569 | 0.89 | CCNA2 (0.52) | CDK2CCNA2CCNA1ALDH1A1 | |
| SCHEMBL5226690 | 0.78 | MAPK1 (0.42) | CDK2CCNA2CCNA1ALDH1A1CCNE1 | |
| SCHEMBL5230295 | 0.77 | CCNA2 (0.53) | CDK2CCNA2CCNA1ALDH1A1TRPV1 | |
| SCHEMBL5230389 | 0.77 | CCNA2 (0.54) | CDK2CCNA2CCNA1ALDH1A1 | |
| SCHEMBL5228714 | 0.77 | ROCK2 (0.45) | CDK2CCNA2CCNA1ALDH1A1CCNE1 | |
| SCHEMBL5227808 | 0.77 | CCNA2 (0.43) | CDK2CCNA2CCNA1 | |
| SCHEMBL5230469 | 0.77 | CDK2 (0.52) | CDK2CCNA2CCNA1TRPV1CCNE1 | |
| SCHEMBL5230705 | 0.77 | CDK2 (0.52) | CDK2CCNA2CCNA1TRPV1LMNA | |
| SCHEMBL5228781 | 0.76 | CCNA2 (0.54) | CDK2CCNA2CCNA1ALDH1A1TRPV1 | |
| SCHEMBL5229177 | 0.76 | CCNA2 (0.50) | CDK2CCNA2CCNA1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1478357-B1 | TRICYCLIC PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PFIZER ITALIA SRL (IT) | 2007-01-31 | — | — | EP | claimed |
| US-20050176796-A1 | Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents | PHARMACIA ITALIA S.P.A. (IT) | 2005-08-11 | — | — | US | claimed |
| EP-1478357-B1 | TRICYCLIC PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PFIZER ITALIA SRL (IT) | 2007-01-31 | — | — | EP | disclosed |
| US-20050176796-A1 | Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents | PHARMACIA ITALIA S.P.A. (IT) | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176796-A1 | Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents | TP53, NFATC1, MAP3K15 | CDK2 178/4885CCNA2 1338/4885CCNA1 1187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.